Skip to main content
. 2015 Mar 30;6(13):10964–10977. doi: 10.18632/oncotarget.3696

Figure 6. miR-942 is upregulated by c-myc and clinically corelated with c-myc and β-catenin.

Figure 6

(A) Upper: the exact binding sites of c-myc on the human miR-942 promoter. Down: schematic illustration of the cloned fragments of the human miR-942 promoter. E-box1 and E-box2 were mutated to identify which site is essential for c-myc regulation. (B) Real-time PCR analysis of miR-942 expression in the cells transfected with c-myc or c-myc siRNA. Transcript levels were normalized by U6 expression. c-myc affects the transactivity of miR-942 promoter with or without E-boxes. (C) ChIP-qPCR analyses for the fold enrichment of c-myc at the different promoter regions of human miR-942 in Eca109 cells. (D) Analysis of expression of miR-942 with the expression levels of c-myc and nuclear β-catenin in 10 freshly collected human ESCC samples. The ratio of fifth sample (c-myc /α-tubulin, beta-catenin /α-tubulin) was considered as 1.0. Each bar represents the mean ± SD of three independent experiments.